Status:
COMPLETED
Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant
Lead Sponsor:
University of Michigan
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
5+ years
Phase:
NA
Brief Summary
The primary purpose of this research is to determine if it is feasible to perform serial magnetic resonance imaging (MRI) to evaluate the amount of bone marrow cells (also called cellularity) and iron...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age ≥ 5 years.
- Diagnosis of SCD (\[Hemoglobin SS (Hb-SS), Hemoglobin SC (Hb-SC) or Hemoglobin S-Beta thalassemia (Hb-Sβ) genotype\].
- Patient is a candidate for an allogeneic HCT.
- Subject or guardians have given informed consent.
- Exclusion Criteria
- The need for general anesthesia for MRI.
- Subjects with implanted magnetic devices (e.g. pacemakers) that may malfunction or move in the strong magnetic field.
- A subject who is pregnant.
- Previous HCT.
Exclusion
Key Trial Info
Start Date :
May 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03458897
Start Date
May 3 2018
End Date
September 1 2020
Last Update
November 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109